| Zaja, Francesco |
NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 870 | Europe | R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance) | Prof. Dr. M. Dreyling (co-chairman), Klinikum der Universitaet Muenchen | Mantle Cell Lymphoma | 05/21 | 05/26 | | |
|
NCT03764618 / 2018-004774-97: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA |
|
|
| Recruiting | 3 | 90 | Europe, Canada, US, RoW | Fostamatinib disodium, R935788, Fostamatinib, Placebo | Rigel Pharmaceuticals | Warm Antibody Autoimmune Hemolytic Anemia | 10/21 | 03/22 | | |
|
|
|
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma |
|
|
| Recruiting | 3 | 200 | Europe | R-pola-mini-CHP, R-mini-CHOP | Nordic Lymphoma Group, Roche Pharma AG | DLBCL, Diffuse Large B Cell Lymphoma | 02/23 | 02/26 | | |
| Not yet recruiting | 3 | 430 | Europe | Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses | Fondazione Italiana Linfomi ONLUS, GRADE Onlus | Diffuse Large B-Cell Lymphoma, Elderly Patients | 09/25 | 09/30 | | |
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma |
|
|
| Not yet recruiting | 3 | 602 | Europe | Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B) | Fondazione Italiana Linfomi ONLUS | Follicular Lymphoma | 07/28 | 07/30 | | |
NCT01009970 / 2009-012143-42: Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma |
 | P2 data - ASCO |
|
|
| Recruiting | 2 | 50 | Europe | Rituximab, Cyclophosphamide, Vincristine, Prednisone, Doxorubicin | Fondazione Italiana Linfomi ONLUS | Diffuse Large B-Cell Lymphoma | 05/11 | 05/12 | | |
|
FIL_KLIMT, NCT03891355: Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL |
|
|
| Active, not recruiting | 2 | 16 | Europe | Carfilzomib, Lenalidomide, Dexamethasone | Fondazione Italiana Linfomi ONLUS | Mantle Cell Lymphoma | 12/20 | 04/22 | | |
NCT04251065: A Multicenter Clinical Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin in Patients With Relapsed/Refractory CD38 Positive PTCL-NOS, Angioimmunoblastic T-cell Lymphoma AITL and Other Nodal Lymphomas of T Follicular Helper Cells Origin |
|
|
| Recruiting | 2 | 35 | Europe | Daratumumab, Darzalex | Fondazione Italiana Linfomi ONLUS | Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma | 03/22 | 12/23 | | |
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance |
|
|
| Recruiting | 2 | 90 | Europe | Ibrutinib, IMBRUVICA (commercial name) | Fondazione Italiana Linfomi ONLUS, Janssen-Cilag S.p.A. | DLBCL | 02/23 | 02/25 | | |
| Recruiting | 2 | 149 | Europe | Chemotherapy + Blinatumomab | Gruppo Italiano Malattie EMatologiche dell'Adulto, Amgen S.r.l., A.I.L Associazione Italiana contro le Leucemie | Acute Lymphoid Leukemia, Philadelphia Chromosome-Negative B-Cell Precursor | 08/23 | 08/23 | | |
| | N/A | 190 | Europe | | Azienda Sanitaria-Universitaria Integrata di Udine | Thrombocytopenia | | | | |
NCT04454580: Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy |
|
|
| Recruiting | N/A | 15 | Europe | Venetoclax, Azacitidine, Decitabine | Ospedale Maggiore Di Trieste | Acute Myeloid Leukemia, Adult, Hypomethylating Agents, Venetoclax | 09/20 | 09/20 | | |
| Recruiting | N/A | 12 | Europe | Immune checkpoint inhibitor, radiotherapy | Ospedale Maggiore Di Trieste | Hodgkin Lymphoma, Immune Checkpoint Inhibitor, Radiotherapy | 09/20 | 09/20 | | |
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 04/22 | 04/22 | | |
|
|
|
